Clinical Trial Update: Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating weekly oral ixazomib in adults with relapsed/refractory multiple myeloma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2015-08-28